These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9651866)

  • 41. Eudragit RL100 based microspheres for ocular administration of azelastine hydrochloride.
    Shinde UA; Shete JN; Nair HA; Singh KH
    J Microencapsul; 2012; 29(6):511-9. PubMed ID: 22375685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flurbiprofen release from Eudragit RS and RL aqueous nanosuspensions: a kinetic study by DSC and dialysis experiments.
    Castelli F; Messina C; Sarpietro MG; Pignatello R; Puglisi G
    AAPS PharmSciTech; 2002; 3(2):E9. PubMed ID: 12916946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
    Avramoff A; Domb AJ
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid.
    Pecora TM; Musumeci T; Musumeci L; Fresta M; Pignatello R
    Curr Drug Deliv; 2016; 13(7):1165-1175. PubMed ID: 26472468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spray-drying enteric polymers from aqueous solutions: a novel, economic, and environmentally friendly approach to produce pH-responsive microparticles.
    Alhnan MA; Kidia E; Basit AW
    Eur J Pharm Biopharm; 2011 Oct; 79(2):432-9. PubMed ID: 21439376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride.
    Jain SK; Chourasia MK; Sabitha M; Jain R; Jain AK; Ashawat M; Jha AK
    Drug Deliv; 2003; 10(3):169-77. PubMed ID: 12944137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation and characterization of enteric microparticles by coacervation.
    Thomas S; Chong YN; Chaw CS
    Drug Dev Ind Pharm; 2013 Jul; 39(7):1142-51. PubMed ID: 23003201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation and characterization of nebivolol nanoparticles using Eudragit® RS100.
    Jana U; Mohanty AK; Manna PK; Mohanta GP
    Colloids Surf B Biointerfaces; 2014 Jan; 113():269-75. PubMed ID: 24140793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simple and rapid method for the quantification of Eudragit RS100 and RL100 poly(methacrylates) in sustained-release dosage forms.
    Melia CD; Hansraj BR; Khan KA; Wilding IR
    Pharm Res; 1991 Jul; 8(7):899-902. PubMed ID: 1924142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacodynamics of diclofenac from novel Eudragit entrapped microspheres.
    Momoh MA; Kenechukwu FC; Adedokun MO; Odo CE; Attama AA
    Drug Deliv; 2014 May; 21(3):193-203. PubMed ID: 24171400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cationic Eudragit® polymers as excipients for microparticles prepared by solvent evaporation method.
    Vysloužil J; Bavoľárová J; Kejdušová M; Vetchý D; Dvořáčková K
    Ceska Slov Farm; 2013 Dec; 62(6):249-54. PubMed ID: 24393112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eudragit NE40-drug mixed coating system for controlling drug release of core pellets.
    Rahman NU; Yuen KH
    Drug Dev Ind Pharm; 2005 May; 31(4-5):339-47. PubMed ID: 16093199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antioxidant activity and photostability assessment of trans-resveratrol acrylate microspheres.
    Pignatello R; Pecora TMG; Cutuli GG; Catalfo A; De Guidi G; Ruozi B; Tosi G; Cianciolo S; Musumeci T
    Pharm Dev Technol; 2019 Feb; 24(2):222-234. PubMed ID: 29565215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preparation and analgesic activity of Eudragit RS100 microparticles containing diflunisal.
    Pignatello R; Amico D; Chiechio S; Spadaro C; Puglisi G; Giunchedi P
    Drug Deliv; 2001; 8(1):35-45. PubMed ID: 11280442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system.
    Sun C; Liu H; Zhao X; He H; Pan W
    Drug Dev Ind Pharm; 2013 Jan; 39(1):62-6. PubMed ID: 22339081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microencapsulation of chloroquine diphosphate by Eudragit RS100.
    Ndesendo VM; Meixner W; Korsatko W; Korsatko-Wabnegg B
    J Microencapsul; 1996; 13(1):1-8. PubMed ID: 8903781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of extended release coevaporates and coprecipitates of promethazine HCl with acrylic polymers: formulation considerations.
    Dahiya S; Pathak K; Sharma R
    Chem Pharm Bull (Tokyo); 2008 Apr; 56(4):504-8. PubMed ID: 18379098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of dissolution medium agitation on release profiles of sustained-release tablets.
    Paulo ; Sousa Lobo JM
    Drug Dev Ind Pharm; 2001 Sep; 27(8):811-7. PubMed ID: 11699832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel use of Eudragit NE 30D/Eudragit L 30D-55 blends as functional coating materials in time-delayed drug release applications.
    El-Malah Y; Nazzal S
    Int J Pharm; 2008 Jun; 357(1-2):219-27. PubMed ID: 18353571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of the influence of the pH media dissolution, degree of polymerization, and degree of swelling of the polymers on the mechanism of release of diltiazem from matrices based on mixtures of chitosan/alginate.
    Tapia C; Costa E; Moris M; Sapag-Hagar J; Valenzuela F; Basualto C
    Drug Dev Ind Pharm; 2002; 28(2):217-24. PubMed ID: 11926366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.